[1]
Povero, M. et al. 2021. Cost-Effectiveness Analysis of Alirocumab in High Cardiovascular-Risk Patients in Italy. Farmeconomia. Health economics and therapeutic pathways. 22, 1 (Jun. 2021). DOI:https://doi.org/10.7175/fe.v22i1.1499.